BioCentury | May 29, 2020
Product Development

‘A science problem we can solve:’ a BioCentury podcast

The scientific progress toward finding countermeasures against COVID-19 in the past five months is “unprecedented in the history of the world,” GSK’s Hal Barron said on the latest BioCentury This Week - Special Report podcast . Barron,...
BioCentury | Jan 25, 2020
Product Development

Radiotherapy blasts forward

High-wattage takeouts and commercial launches have revived interest in radiopharmaceuticals for cancer. The challenge for the new wave of candidates is to achieve enough differentiation to justify the logistical hurdles of manufacturing and delivering products...
BC Extra | Jan 13, 2020
Clinical News

Adaptimmune rises on early promise for SPEAR TCR cell therapies in solid tumors

Cancer cell therapy play Adaptimmune gained $2.66 (200%) to $3.99 on Monday after announcing a new set of data for its SPEAR T cell therapies in four different solid tumor indications. The announcement by Adaptimmune...
BC Extra | Nov 7, 2019
Clinical News

First U.S. clinical CRISPR data give early safety signal for ex vivo editing

CRISPR cleared its earliest safety hurdle with the first clinical data on the gene editing technology in the U.S., but it's still too early to tell whether that safety signal will persist and apply to...
BC Extra | Nov 6, 2019
Financial News

A2 emerges with $57M series A, engineered T cells for solid tumors

A2 debuted Tuesday with a $57 million series A round and two T cell immunotherapy strategies for solid tumors. The Column Group led the tranched round, with participation by Vida Ventures, Samsara BioCapital and Nextech...
BioCentury | Nov 1, 2019
Emerging Company Profile

Tmunity: Manufacturing momentum for CAR and TCR therapies

Tmunity’s $75 million series B round will enable the company to keep advancing its CMC capabilities alongside its clinical and preclinical engineered CAR and TCR therapies for solid and blood tumors. Andreessen Horowitz (a16z) led...
BioCentury | Oct 19, 2019
Product Development

How GSK has rebuilt its oncology pipeline from the ground up

Less than two years into GSK's cancer rebuild, Hal Barron is making measurable strides to reposition the pharma as an immunology-focused company. His turnaround boasts an expanded immuno-oncology pipeline, replete with multiple modalities, and two...
BC Extra | Oct 9, 2019
Company News

GSK partners with Lyell to bring gene, cell therapies into solid tumors

As GSK looks to expand its cell and gene therapy pipeline, the pharma has partnered with Lyell to take the modalities into solid tumors by improving T cell functionality and manufacturing. Lyell Immunopharma Inc. is...
BC Innovations | Sep 12, 2019
Emerging Company Profile

Valo: adding tumor antigens to oncolytic viruses

With platforms that can rapidly display tumor-specific antigens on oncolytic viruses without genetic engineering, Valo is positioning itself as an attractive collaborator for immuno-oncology companies. Oncolytic viruses kill cancer cells by lysing the cells, and...
BC Innovations | Jul 26, 2019
Product Development

Institute for Protein Design's de novo revolution

Seattle's Institute for Protein Design is growing an army of spinouts that build proteins from the ground up. With applications ranging from multivalent vaccines and synthetic cytokines to precision cell therapies, these companies could put...
Items per page:
1 - 10 of 150